Anti-A blood group antibody (Anti-A)

Anti-A blood group antibodies, also known as anti-A isoagglutinins, are naturally occurring antibodies found in the plasma of individuals with blood group B or O (StatPearls, NBK554444). These antibodies, typically of the IgM and IgG classes, specifically recognize the A-antigen (N-acetylgalactosamine) expressed on the surface of erythrocytes and endothelial cells (NIH, NBK2267). In clinical medicine, they represent a primary barrier to safe blood transfusions and organ transplantations, as their binding can trigger rapid complement-mediated hemolysis or hyperacute graft rejection (NCBI, PMC3159240). Therapeutic strategies to manage these antibodies include extracorporeal removal via plasmapheresis or immunoadsorption, and pharmacological suppression using B-cell depleting agents like rituximab or plasma cell inhibitors like bortezomib (PubMed, 25639155). Emerging treatments also explore the use of glycan-based decoys to neutralize circulating anti-A antibodies before they can cause tissue damage (Journal of Clinical Investigation, 129(12)). Monitoring of anti-A titers is essential for the management of ABO-incompatible procedures and the prevention of hemolytic disease of the newborn (Wikipedia, ABO blood group system).

Other names

Anti-A isoagglutininAnti-A agglutininBlood group A antibodyAlpha-agglutinin

Therapeutic strategies targeting anti-A antibodies involve B-cell depletion to halt production, proteasome inhibition to induce plasma cell apoptosis, complement cascade blockade to prevent hemolysis, and direct enzymatic cleavage or glycan-based neutralization of the antibodies themselves.